JP2023135645A5 - - Google Patents
Info
- Publication number
- JP2023135645A5 JP2023135645A5 JP2023039397A JP2023039397A JP2023135645A5 JP 2023135645 A5 JP2023135645 A5 JP 2023135645A5 JP 2023039397 A JP2023039397 A JP 2023039397A JP 2023039397 A JP2023039397 A JP 2023039397A JP 2023135645 A5 JP2023135645 A5 JP 2023135645A5
- Authority
- JP
- Japan
- Prior art keywords
- fusion protein
- vegf receptor
- approximately
- receptor fusion
- weeks
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (20)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263319865P | 2022-03-15 | 2022-03-15 | |
| US63/319,865 | 2022-03-15 | ||
| US202263404511P | 2022-09-07 | 2022-09-07 | |
| US63/404,511 | 2022-09-07 | ||
| US202263404889P | 2022-09-08 | 2022-09-08 | |
| US63/404,889 | 2022-09-08 | ||
| US202263411589P | 2022-09-29 | 2022-09-29 | |
| US63/411,589 | 2022-09-29 | ||
| US202263412158P | 2022-09-30 | 2022-09-30 | |
| US63/412,158 | 2022-09-30 | ||
| US202263421296P | 2022-11-01 | 2022-11-01 | |
| US63/421,296 | 2022-11-01 | ||
| US202263434918P | 2022-12-22 | 2022-12-22 | |
| US63/434,918 | 2022-12-22 | ||
| US202363444470P | 2023-02-09 | 2023-02-09 | |
| US63/444,470 | 2023-02-09 | ||
| US202363447577P | 2023-02-22 | 2023-02-22 | |
| CA3,190,726 | 2023-02-22 | ||
| CA3190726A CA3190726A1 (en) | 2022-03-15 | 2023-02-22 | Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders |
| US63/447,577 | 2023-02-22 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023135645A JP2023135645A (ja) | 2023-09-28 |
| JP2023135645A5 true JP2023135645A5 (enExample) | 2026-03-24 |
Family
ID=85703566
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023039397A Pending JP2023135645A (ja) | 2022-03-15 | 2023-03-14 | 血管新生性眼障害の処置のための長期高用量ｖｅｇｆアンタゴニストレジメン |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230295266A1 (enExample) |
| EP (1) | EP4245313A1 (enExample) |
| JP (1) | JP2023135645A (enExample) |
| KR (1) | KR20230135012A (enExample) |
| CN (1) | CN119365206A (enExample) |
| AU (2) | AU2023234355A1 (enExample) |
| CA (1) | CA3254467A1 (enExample) |
| CL (2) | CL2024002718A1 (enExample) |
| IL (1) | IL315347A (enExample) |
| JO (1) | JOP20240198A1 (enExample) |
| MX (1) | MX2024011132A (enExample) |
| TW (1) | TW202400215A (enExample) |
| WO (1) | WO2023177689A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20240329A1 (es) | 2019-06-05 | 2024-02-27 | Regeneron Pharma | Dispositivos y metodos para administracion de dosis de precision |
| FI4185318T3 (fi) | 2021-05-17 | 2025-10-13 | Regeneron Pharma | Pitkäaikaisia, suuren annoksen VEGF-antagonistihoitoja angiogeenisten silmäsairauksien hoitoon |
| US12649031B2 (en) | 2021-09-08 | 2026-06-09 | Regeneron Pharmaceuticals, Inc. | Methods for delivering agents with pre-filled syringes to minimize intraocular inflammation |
| USD1120314S1 (en) | 2022-11-30 | 2026-03-24 | Regeneron Pharmaceuticals, Inc. | Dose delivery device |
| CN121712520A (zh) | 2023-06-23 | 2026-03-20 | 瑞泽恩制药公司 | 用于治疗血管生成性眼病的延长的高剂量vegf拮抗剂方案 |
| WO2025166292A1 (en) * | 2024-02-02 | 2025-08-07 | Kodiak Sciences Inc. | Methods of treating eye disorders |
| CN117805397A (zh) * | 2024-02-29 | 2024-04-02 | 军科正源（北京）药物研究有限责任公司 | 检测游离vegf的方法 |
| WO2026019840A1 (en) * | 2024-07-16 | 2026-01-22 | 4D Molecular Therapeutics Inc. | Methods for treating diabetic macular edema with adeno-associated virus |
| KR20260096819A (ko) * | 2024-12-13 | 2026-06-24 | 리제너론 파아마슈티컬스, 인크. | 망막 정맥 폐쇄에 속발하는 혈관신생 눈 장애의 치료를 위한 연장된 고용량 vegf 길항제 레지먼 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7396664B2 (en) | 1999-06-08 | 2008-07-08 | Regeneron Pharmaceuticals, Inc. | VEGF-binding fusion proteins and nucleic acids encoding the same |
| AR046510A1 (es) | 2003-07-25 | 2005-12-14 | Regeneron Pharma | Composicion de un antagonista de vegf y un agente anti-proliferativo |
| ES2381014T3 (es) | 2004-06-08 | 2012-05-22 | Chengdu Kanghong Biotechnologies Co., Ltd. | Proteína quimérica inhibidora de la angiogénesis y el uso |
| CN100502945C (zh) | 2006-03-31 | 2009-06-24 | 成都康弘生物科技有限公司 | Vegf受体融合蛋白在治疗眼睛疾病中的应用 |
| KR20200093621A (ko) * | 2017-11-30 | 2020-08-05 | 리제너론 파아마슈티컬스, 인크. | 혈관형성 눈 장애를 치료하기 위한 vegf 길항제의 용도 |
| IL318292A (en) | 2017-12-13 | 2025-03-01 | Regeneron Pharma | Devices and methods for administering precise doses |
| RS67656B1 (sr) | 2018-05-10 | 2026-02-27 | Regeneron Pharma | Formulacije koje sadrže visoke koncentracije fuzionog proteina vegf receptora |
| PE20240329A1 (es) | 2019-06-05 | 2024-02-27 | Regeneron Pharma | Dispositivos y metodos para administracion de dosis de precision |
| AU2020326243A1 (en) * | 2019-08-06 | 2022-02-17 | F. Hoffmann-La Roche Ag | Personalized treatment of ophthalmologic diseases |
| CN114867487A (zh) * | 2019-11-25 | 2022-08-05 | 加利福尼亚大学董事会 | 用于眼内新生血管的长效vegf抑制剂 |
| US11944663B2 (en) * | 2020-06-18 | 2024-04-02 | Chengdu Kanghong Biotechnologies Co. Ltd. | Method for treating angiogenic eye disorders using VEGF antagonists |
| FI4185318T3 (fi) * | 2021-05-17 | 2025-10-13 | Regeneron Pharma | Pitkäaikaisia, suuren annoksen VEGF-antagonistihoitoja angiogeenisten silmäsairauksien hoitoon |
-
2023
- 2023-03-14 US US18/121,490 patent/US20230295266A1/en active Pending
- 2023-03-14 IL IL315347A patent/IL315347A/en unknown
- 2023-03-14 JP JP2023039397A patent/JP2023135645A/ja active Pending
- 2023-03-14 CN CN202380025696.0A patent/CN119365206A/zh active Pending
- 2023-03-14 AU AU2023234355A patent/AU2023234355A1/en active Pending
- 2023-03-14 WO PCT/US2023/015223 patent/WO2023177689A1/en not_active Ceased
- 2023-03-14 CA CA3254467A patent/CA3254467A1/en active Pending
- 2023-03-15 KR KR1020230034203A patent/KR20230135012A/ko active Pending
- 2023-03-15 EP EP23162091.5A patent/EP4245313A1/en active Pending
- 2023-03-15 TW TW112109574A patent/TW202400215A/zh unknown
- 2023-03-15 AU AU2023201635A patent/AU2023201635A1/en active Pending
-
2024
- 2024-09-10 CL CL2024002718A patent/CL2024002718A1/es unknown
- 2024-09-11 MX MX2024011132A patent/MX2024011132A/es unknown
- 2024-09-11 JO JOJO/P/2024/0198A patent/JOP20240198A1/ar unknown
-
2025
- 2025-06-17 CL CL2025001801A patent/CL2025001801A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12168036B2 (en) | Methods for treating angiogenic eye disorders with high doses of VEGF receptor fusion proteins | |
| JP2023135646A5 (enExample) | ||
| AU2022275786B2 (en) | Extended, high dose VEGF antagonist regimens for treatment of angiogenic eye disorders | |
| EP4245313A1 (en) | Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders | |
| US20240024420A1 (en) | Extended, High Dose VEGF Antagonist Regimens for Treatment of Angiogenic Eye Disorders | |
| KR102373289B1 (ko) | 지속성 부종을 갖는 삼출성 노인성 황반변성을 치료하기 위한 시롤리무스의 용도 | |
| JP2024519629A5 (enExample) | ||
| EP4480491A1 (en) | Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders | |
| HK40099475A (en) | Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders | |
| HK40099476A (en) | Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders | |
| HK40106296B (en) | High concentration vegf receptor fusion protein containing formulations | |
| CA3190726A1 (en) | Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders | |
| HK40106296A (en) | High concentration vegf receptor fusion protein containing formulations | |
| WO2025219484A1 (en) | High concentration aflibercept formulations | |
| HK40119109A (en) | Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders | |
| HK40052983A (zh) | 含有高浓度vegf受体融合蛋白的制剂 | |
| HK40052983B (zh) | 含有高浓度vegf受体融合蛋白的制剂 | |
| HK40000827A (en) | Use of sirolimus to treat exudative age-related macular degeneration with persistent edema |